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Abstract
Intellectual disability (ID) and autism spectrum disorders (ASDs)
are complex neuropsychiatric conditions, with overlapping clinical
boundaries in many patients. We identified a novel intragenic dele-
tion of maternal origin in two siblings with mild ID and epilepsy in
the CADPS2 gene, encoding for a synaptic protein involved in
neurotrophin release and interaction with dopamine receptor type
2 (D2DR). Mutation screening of 223 additional patients (187 with
ASD and 36 with ID) identified a missense change of maternal
origin disrupting CADPS2/D2DR interaction. CADPS2 allelic expres-
sion was tested in blood and different adult human brain regions,
revealing that the gene was monoallelically expressed in blood
and amygdala, and the expressed allele was the one of maternal
origin. Cadps2 gene expression performed in mice at different
developmental stages was biallelic in the postnatal and adult
stages; however, a monoallelic (maternal) expression was
detected in the embryonal stage, suggesting that CADPS2 is
subjected to tissue- and temporal-specific regulation in human
and mice. We suggest that CADPS2 variants may contribute to ID/
ASD development, possibly through a parent-of-origin effect.
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Introduction
Intellectual disability (ID) is a neurodevelopmental disorder charac-
terized by a below-average score on tests of mental ability and limi-
tations in daily life functions, with a frequency of 1–3% (van
Bokhoven, 2011). Autism spectrum disorders (ASDs) are character-
ized by impaired social interactions and communication and stereo-
typed behaviors with onset before 3 years of age. ASDs are
currently estimated to affect ~1% of children (Autism and Develop-
mental Disabilities Monitoring Network 2009) and significantly
skewed toward boys, with a sex ratio of 4:1(Fombonne, 2005).
Although many monogenic and chromosomal causes of ID are
known, a “multiple hit”/oligogenic model is emerging, where
combinations of variants are necessary to disrupt normal neuronal
development and underlie a range of disorders from idiopathic
epilepsy to autism and ID (Coe et al, 2012). Many genes involved in
synaptic function were shown to play a role in neurodevelopmental
disorders (Gilman et al, 2011). Nevertheless, although definite
epidemiological data are lacking, causative mutations remain
unknown in the majority of ID/ASD patients.
We have identified a novel intragenic deletion and a potentially
deleterious rare single nucleotide variant (SNV) in the Ca2+-
dependent activator protein for secretion 2 (CADPS2) gene, leading
to the disruption of its interaction with the dopamine receptor type
2 (D2DR; Binda et al, 2005), in individuals with either ASD/ID.
CADPS2 is an excellent candidate for neurologic development
abnormalities, given that it is predominantly expressed in the
nervous system, and is involved in neurotrophin-3 (NT-3) and
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brain-derived neurotrophic factor (BDNF) release (Sadakata &
Furuichi, 2009, 2010). CADPS2 maps to the “autism susceptibility
locus 1” on chromosome 7q31-q33(Lamb et al, 2005) and is one
of the genes that were shown to be downregulated in brains of
autistic individuals (Voineagu et al, 2011).
The new functional SNV (p. Asp1113Asn) is of maternal origin,
and also the novel intragenic deletion is maternally inherited. We
show for the first time that CADPS2 is maternally expressed in
human blood and amygdala. We identified a cluster of differentially
methylated CpG regions in the first intron of the gene, in bisulfite-
treated DNA from the blood and amygdala. The differential methyla-
tion in this region is not observed in other brain areas, such as the
cerebellum, where we found a biallelic expression of the gene.
However, we could not identify a reproducible parent-of-origin
methylation profile for these CpGs, suggesting that other genomic
regions in CADPS2 or other regulatory mechanisms may be related
to the presence of a monoallelic pattern of expression.
In adult mice, we observed a biallelic expression of the gene in
all the postnatal and adult stages analyzed; however, we found a
monoallelic maternal expression in the cerebellum at the embryonal
stage E17.5. Therefore, we suggest that CADPS2 is subjected to a
fine temporal- and tissue-specific regulation, leading to a maternally
expressed gene, where inherited mutations may contribute to the
ID/ASD phenotype.
Results
Identification of a novel intragenic deletion in CADPS2
We ascertained a pair of siblings (male and female) with behavioral
problems, borderline ID, and epilepsy. Array-CGH analysis detected
an intragenic deletion of ~285 kb in CADPS2 on chromosome
7q31.32 in both siblings, likely to be inherited from the deceased
mother, since the father did not carry it (Fig 1A and B, and Supple-
mentary Fig S1A).
The deletion was confirmed to be of maternal origin, by micro-
satellite markers and single nucleotide polymorphisms (SNPs)
analysis, as shown in Fig 1B.
No deletions overlapping CADPS2 are present in the Database of
Genomic Variants (DGV), and this CNV was not present in ISCA
(https://www.iscaconsortium.org/index.php) and Troina (http://
gvarianti.homelinux.net/gvariantib37/index.php) databases. Only a
small duplication overlapping exon 1 has been reported (Shaikh
et al, 2009).
Two additional CNVs were identified in the affected siblings, but
since they were already reported in DGV (Database of Genomic
Variants) and defined non-pathogenic, we did not further character-
ize them (Supplementary Table S1).
We mapped the deletion boundaries between intron 3 and intron
28 of CADPS2 via quantitative PCR (Fig 1C) and defined by long-
range PCR the deletion breakpoint between bp 121,984,852–
122,270,267 of chromosome 7 (hg19) (Fig 1D). Sequencing of
CADPS2-coding exons in the two siblings excluded the presence of
additional variants. Interestingly, we could not detect any CADPS2
transcripts by RT–PCR, neither the wild-type nor in the aberrant
one, in the blood of the two affected siblings (Supplementary Fig
S1B and C).
CADPS2 mutation screening in ASD/ID patients
Thirty-six Italian patients with ID and 187 probands with ASD [of
which 94 from Italy and 93 from the International Molecular Genetic
Study of Autism Consortium (IMGSAC) collection (IMGSAC, 2001)]
were recruited for mutation screening of all exon and exon–intron
boundaries of the CADPS2 gene (NM_017954.10). Clinical character-
istics of Italian ASD and ID individuals are reported in Supplemen-
tary Tables S1A and B, and clinical characteristics and inclusion
criteria of IMGSAC ASD individuals have been previously reported
(IMGSAC, 2001). Two synonymous (p. Ala26= and p. Ala402=) and
five missense (p. Met630Thr, p. Phe645Val, p. Asp1088Asn,
p. Asp1113Asn, and p.Val1137Met) heterozygous rare variants were
identified (Table 1). Analysis of parental DNA indicated that all
these variants were inherited (Fig 1E). Four missense changes were
present in public databases (dbSNP, EVS), and their frequencies
were not statistically different from the ones identified in our
ASD/ID patients. In addition, the paternally inherited change
p. Asp1088Asn did not co-segregate with the disease phenotype in
the two ASD multiplex families where it was identified (Fig 1E).
Three variants were novel: p. Ala402=, p. Ala26=, p. Asp1113Asn,
and their frequency in the AD/ID group was statistically different
form the control group (P-value = 0.0467; Fisher’s t-test; 500 Italian
chromosomes and EVS database). For the silent variants, no functional
effect at the transcript level could be detected by RT–PCR or
predicted by informatic tools such as ESE finder v3.0 and Human
Splicing Finder (HSF) v2.4.1; hence, their functional effect was not
tested further. Therefore, we focused on the p. Asp1113Asn
missense variant for further functional studies, because this was the
only one absent in all the databases and in the Italian controls and
predicted damaging by PolyPhen-2 (PolyPhen score = 0.936;
Table 1; Adzhubei et al, 2013).
The novel change p.Asp1113Asn in CADPS2 disrupts the
interaction with dopamine receptor type 2
We assessed the functional effect of the novel variant p.Asp1113Asn
in the binding to dopamine receptor type 2 (D2DR), one of the few
known interactors of CADPS2 (Binda et al, 2005), compared to
wild-type CADPS2. After transfecting the different CADPS2 cDNA
clones in frame with a C-terminal V5 tag into the SHSY5Y cell line,
derived from neuroblastoma and expressing dopaminergic markers
(Sabens & Mieyal, 2010), co-immunoprecipitation assays of the
corresponding cell lysates with an anti-D2DR antibody and Western
blot analysis against the V5 tag showed that the novel missense
change p. Asp1113Asn decreased the protein–protein interaction
between CADPS2 and D2DR (Fig 1F). Co-immunoprecipitation with
anti-V5 antibody and western blotting analysis against D2DR
confirmed that the missense change interfered with CADPS2 and
D2DR binding (Supplementary Fig S2).
CADPS2 allelic expression analysis reveals that the gene is
maternally expressed in blood
We noticed that the majority of the missense variants that were
absent in Italian controls and co-segregated with the phenotype
were of maternal origin, including the novel p. Asp1113Asn func-
tional change (Fig 1F). Furthermore, the novel intragenic CADPS2
EMBO Molecular Medicine Vol 6 | No 6 | 2014 ª 2014 The Authors
EMBO Molecular Medicine Maternally expressed CADPS2 gene in ASD/ID Elena Bonora et al
796
Published online: April 14, 2014 
deletion is of maternal origin, as shown in Fig 1B. Thus, we decided
to test whether CADPS2 might be subjected to a parent-of-origin
regulation.
We first investigated the allelic expression of two CADPS2 coding
SNPs rs2251761 (exon 3) and rs2074589 (exon 17) in informative
heterozygous controls of whom blood RNA was available. As shown
in Fig 2A, in heterozygous individuals, only one allele was
expressed in blood cDNA, both for rs2251761 (3 independent
controls tested) and for rs2074589 (4 independent controls tested).
In order to establish whether the expressed allele was of maternal
origin, we analyzed three different families for whom genomic DNA
and blood mRNA of heterozygous individuals were available. One
multigenerational family of controls was informative for SNP
rs2251761. Segregation and expression analysis of the SNP showed
that the CADPS2 expressed allele in III-1 was of maternal origin
(Fig 2B). In the family with the synonymous variant p. Ala402= the
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Figure 1. CADPS2 deletion mapping and parental origin of CADPS2 coding variants.
A Family tree of the ID sibs carrying the novel intragenic deletion.
B Microsatellite and SNP analysis showing the maternal inheritance of CADPS2 intragenic deletion.
C Fine mapping of CADPS2 deletion by real-time qPCR using different probes across the region. All data were normalized using as reference gene FOXP2.
D CADPS2 deletion breakpoint mapping, showing the insertion of 3 base pairs at the breakpoint (upper panel) and the corresponding location on chromosome 7q (UCSC
Genome Browser).
E Parental origin of the coding CADPS2 variants identified in the mutation screening. In blue are indicated the synonymous changes, and in red the missense changes.
It is worth noting that in the family with more than one sib, the maternal variant p.Val1137Met was transmitted to the affected son (ID case) and not to the
unaffected brother.
F Analysis of the effect of CADPS2 variant p. Asp1113Asn in D2DR binding, in SHSY5Y cells transfected with the different CADPS2 constructs tagged with V5 epitope tag:
Immunoprecipitation was performed with a rabbit anti-D2DR antibody; western blotting was performed with a mouse anti-V5 tag antibody (first three panels) and
with a rabbit anti-D2DR antibody; lowest panel: western blot for c-tubulin on total cell lysates, as internal control of protein quantity. Second panel, lane 3: the
co-immunoprecipitated CADPS2_Asp1113Asn_V5 is clearly diminished compared to wild-type (lane 2); the immunoblots are representative of three independent
experiments.
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heterozygous father expressed only the C allele in blood cDNA,
while the affected child expressed only the maternal wild-type G
allele (Fig 2C). In the family carrying the p.Val1137Met variant, the
expressed allele in the affected ID individual was the maternally
inherited A allele, whereas the healthy mother expressed the wild-
type G allele (Fig 2D). These results indicate that CADPS2 is mater-
nally expressed in blood. As mentioned earlier, in the 2 siblings with
the maternal CADPS2 deletion, no CADPS2 mRNA could be detected
in the blood, in agreement with the lack of expression of the paternal
copy of the gene.
CADPS2 allelic expression analysis in brain
Different human brain regions were analyzed to study CADPS2
expression. For three adult controls, heterozygous at SNP
rs2251761, RNA from amygdala, cerebellum, cerebral cortex, and
entorhinal cortex was available. RT–PCR analysis showed high
expression level in cerebellum and cerebral cortex and a lower
expression in amygdala and entorhinal cortex (Fig 2E, upper panel).
Sequencing of the PCR products showed that CADPS2 was always
monoallelically expressed in the amygdala, whereas it was biallelic
in the other areas (Fig 2F). CADPS2 expression analysis in blood
cDNA of the same individuals confirmed the monoallelic expression
and indicated that the same allele was expressed in both amygdala
and blood. These results suggested that CADPS2 might be subjected
to tissue-specific monoallelic expression and putative imprinting.
Quantitative methylation analysis of CADPS2 CpG regions
We undertook a quantitative epigenetic analysis of CADPS2 CpG
regions located in the promoter and first intron. The EpiDesigner
BETA software was used to predict the CpG islands: Four amplicons
including 92 CpGs were selected (Fig 3A); 63 of these CpGs were
suitable for analysis by gene-specific amplification using in vitro
transcription coupled with mass spectrometry (MS) (Supplementary
Table S2). Analysis was performed on bisulfite-treated DNA
Table 1. Coding variants in CADPS2 identified either in ASD or in ID patients.
Position on
chr7 (hg19)
Type of change
(NP_060424.9)
NM_017954.10
PolyPhen-2
score
(HumDiv)
SIFT prediction
(cutoff =0.05)
Parental
origin
Heta in
ASD/ID
(N=223)
Heta in
Italian
controls
(N=250)
Heta in
EVS
(European-
American)
P valueb
(Fisher’s
t-test)
g.122,526,314G>A
nonec
p. Ala26= na na Maternal 1/223 (ASD) 0 0 0.0467
g.122,255,252G>C
nonec
p. Ala402= na na Paternald 1/223 (ASD) 0 0 0.0467
g.122,114,544A>
Grs199713510c
p. Met630Thr 0.917 (possibly
damaging)
0 (damaging) Paternald 1/223 (ASD) 2/250 10/4113 0.477
g.122,114,500A>C
rs201536376c
p. Phe645Val 0.001 (benign) 0.531 (tolerated) Maternal 1/223 (ASD) 0 9/4128 0.392
g.122027130C>T
rs76528953c
p. Asp1088Asn 1 (probably
damaging)
0.001 (damaging) Paternal 2/223e (ASD) 0 28/4145 0.429
g.122,019,472C>T
nonec
p. Asp1113Asn 0.936 (probably
damaging)
0.039 (tolerated) Maternal 1/223 (ASD) 0 0 0.0467
g.122,001,046C>T
rs200984050c
p. Val1137Met 0.997 (probably
damaging)
0.003 (damaging) Maternal 1/223 (ID) 0 6/4122 0.294
aHet = number of heterozygous individuals.
bFisher’s exact test calculated considering the number of heterozygous individuals in the total control group [Italian and European-American from EVS (http://
evs.gs.washington.edu/EVS/ accession March 2013].
cdbSNP entry reported for the corresponding variant; none = not present in dbSNP.
dThe two paternal changes were present in the same ASD individual.
eThe two individuals from multiplex ASD families inherited the change from the father; however in both cases, it did not co-segregate with the phenotype (see
Fig 1F).
SNVs not found in dbSNP and EVS are shown in bold.
Figure 2. CADPS2 allelic expression in different human tissues.
A Allelic expression in blood cDNA of SNP rs2251761 (A/G alleles) and rs2074589 (A/C alleles) in two heterozygous individuals for the two SNPs: upper panel: sequence
electropherograms from genomic DNA (gDNA) showing the heterozygous state, lower panel: sequence electropherograms from blood cDNA; the SNP position is
shown by the underscore marking.
B Allelic expression from blood cDNA of SNP rs2251761 in an informative control family: the expressed A allele in the offspring inherits it from the mother.
C Allelic expression of the variant p. 402Ala=: the change is inherited from the heterozygous father, who actually expresses only the variant allele in blood, whereas the
affected child expresses only the maternal allele in blood.
D Allelic expression of the variant p. Val1137Met: The maternally inherited variant is the only one expressed in blood cDNA of the affected son, whereas the healthy
mother expresses the wild-type allele. The healthy brother does not inherit the change.
E RT-PCR of CADPS2 expression in different brain areas of one control individual heterozygous at SNP rs2251761; upper panel: PCR products covering CADPS2x1-x4
(encompassing SNP rs2251761); lower panel: PCR products of housekeeping gene GUSBP. Rt- = no reverse transcriptase in reaction; Rt+ = reverse transcriptase added.
F Electropherograms showing CADPS2 allelic expression in different brain areas of one control individual heterozygous at SNP rs2251761. In the lower panel, it is shown
that the allele expressed by amygdala and blood cDNA is the same. gDNA = genomic DNA.
▸
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extracted from blood, on bisulfite-treated DNA extracted from cere-
bellum, amygdala, and blood of one control individual (cnt1;
heterozygous for SNP rs2251761), from amygdala and cerebellum of
a second control (cnt2; heterozygous for SNP rs2251761), and from
amygdala of another control individual (cnt3). One region in IGF2
gene was used as known imprinted gene (Izzi et al, 2012; Supple-
mentary Table S2).
Preliminary analysis on 9 blood DNA (3 ID and 6 control indi-
viduals) showed that the promoter region was unmethylated across
all the three regions analyzed (Fig 3A and B); an example of the
pattern is reported in Fig 3B (amplicon c, Supplementary Table S2).
Conversely, we identified two differentially methylated sites in the
first intron of CADPS2, corresponding to the genomic coordinates:
chr7: 122,525,608 (CpG_15) and 122,525,525 (CpG_16). For these
two sites, cerebellum DNA showed a complete unmethylated status
(Fig 3C and Table 2), whereas in blood and amygdala a consistent
hemimethylated pattern was observed. The differences in methyla-
tion between cerebellum and blood (cnt1) and between cerebellum
and amygdala (cnt2) were significant for both sites (Table 2), also
when comparing the data from cerebella and amygdala from
distinct individuals (CpG15, P-value = 0.0012; CpG16, P-
value = 0.0102; Table 2). No differences were observed in the
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Figure 3. Methylation analysis of CADPS2 promoter and intron 1 CpG regions.
A Upper panel: Epidesigner beta output of CpG prediction in the promoter and intron 1 of CADPS2 genomic region; blue bars = CpG covered by MS analysis, red
bars = CpG that cannot be analyzed by MS analysis, (a,b,d) sequences covered in the MS analysis using a forward primer in the in vitro transcription, (c) sequence
covered by MS analysis using a reverse primer in the in vitro transcription (see text for details); lower panel: transcription factors, CpG island prediction, and
regulatory sites in the corresponding genomic region as reported in UCSC Genome Browser (hg19).
B, C Epityper beta output of CADPS2 promoter and intron 1 quantitative methylation analysis via MS in cerebellum, amygdala, and blood genomic DNA bisulfite-treated
from different individuals; the percentage of differential methylation is indicated by the different shades of gray as shown in the corresponding box; numbers
indicate the base pairs relative to the amplified PCR product (upper lane) and the position of the CpG (lower lane); the differential methylation pattern is
appreciable for CpG_15 and CpG_16 in intron 1.
D Colonies carrying either the T (unmethylated, white circle) or the C (methylated, black circle) alleles at CpG_14, CpG_15, and CpG_16 of CADPS2 from the colonies
obtained by cloning the intron 1 PCR products from bisulfite-treated DNA of cerebellum and blood of individual cnt1.
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methylation pattern for the control region SQNM (corresponding to
the known imprinted gene IGF2). These data were corroborated by
cloning the PCR products of intron 1 obtained from bisulfite-
treated blood and cerebellum DNA of the same individual (cnt1)
and colony screening for the presence of either C (methylated) or
T (unmethylated) alleles at the CpGs (Fig 3D). This approach led
us to analyze also CpG_14 (position 122,525,624) that was not
possible to study with MS. Out of 39 colonies from blood, we
found 43.58% methylation at position 122,525,624 (CpG_14),
48.72% methylation at position 122,525,608 (CpG_15), and
41.03% methylation allele at position 122,525,525 (CpG_16).
Instead, the percentage of colonies derived from the PCR products
of bisulfite-treated cerebellum DNA carrying the methylated allele
was 2.56% at bp122,525,624 (CpG_14), 5.13% at bp122,525,608
(CpG_15), and 2.56% at bp122,525,525 (CpG_16), confirming the
extensive unmethylation observed by MS analysis (Fig 3C). Quanti-
tative data from bisulfite-treated blood DNA from controls and ID
cases (for a total of 34 individuals) confirmed the presence of a
hemimethylated pattern for CpG15 and 16 (Supplementary Table
S3). In order to detect whether these sites (CpG_14, CpG_15,
CpG_16) show a parent-of-origin-specific differential methylation,
we analyzed the methylation status of four control individuals
heterozygous for an adjacent SNP (rs981321, g.122,525,329
G > A), by performing colony analysis of an intron 1 fragment
containing SNP rs981321 and the three CpG sites. In one control
individual, we could detect a statistically significant preferential
methylation of rs981321-A allele at CpG_16 (Fig 4A and B), while
CpG15 and CpG14 did not show a differential methylation pattern
for the two alleles; however, it was not possible to determine the
parental origin of the two alleles in this individual (Fig 4A and B).
For the three other heterozygous controls, the parental origin of
the alleles was known; however, we did not detect a difference in
the methylation level of the maternal and paternal alleles at any of
the three CpGs (Fig 4C).
Cadps2 allelic expression analysis in mice
Cadps2 expression was also evaluated in murine tissues. FVB and
C57B/6 mouse strains were sequenced for two Cadps2 coding SNPs
(Supplementary Table S3). At SNP rs33756726, FVB mice were
homozygous for the C allele and C57B/6 were homozygous for the
T allele (Fig 5A). We analyzed Cadps2 expression in tissues derived
from heterozygous offspring of C57B/6 (mother) × FVB (father)
crosses at different developmental stages: E17.5 d.p.c. (n = 5), P5,
(n = 4), P20 (n = 2) (Fig 5B). Cerebral cortex, kidney, and heart
showed a biallelic expression of Cadps2 mRNA at all stages,
whereas a monoallelic maternal expression was observed in the
embryonic cerebellum (E17.5). This monoallelic expression was not
retained postnatally (P5) and in the adult stage (P20).
RNA from amygdala was available only for mouse adult stage
P20 and Cadps2 expression was biallelic, at difference with the data
obtained from human tissues.
Discussion
We provide evidence that CADPS2 shows tissue-specific monoallelic
expression, with the maternally inherited allele expressed in human
blood and in specific brain regions (in the amygdala at least).
Several studies demonstrated that a region on human chromo-
some 7 contains a cluster of imprinted genes (Riesewijk et al, 1997;
Kosaki et al, 2000; Lee et al, 2000; Schneider et al, 2012), but no
data on CADPS2 regulation have yet been reported. CADPS2 is an
excellent candidate for neurologic development abnormalities, given
that it is predominantly expressed in the nervous system, is
involved in neurotrophin-3 (NT-3) and brain-derived neurotrophic
factor (BDNF) release, and cadps2-knockout mice show abnormali-
ties in neuronal development and impairments in social behavior
(Sadakata et al, 2004, 2006, 2007b; Sadakata & Furuichi, 2009,
2010). Nevertheless, comprehensive data on the role of CADPS2 in
human disorders are still lacking. Some deletions in the region are
reported (see Decipher, ISCA), but are often very large with no
details on phenotype and parent of origin. To our knowledge, only
one large de novo deletion of 5.4 Mb encompassing CADPS2, as
many other genes, was thoroughly described in a 3-year-old child
with an eye disorder (attributed to the deleted TSPAN12), ASD diag-
nosis, dysmorphic features, and occipital epileptic discharges
(Okamoto et al, 2011). A duplication overlapping exon 1 of CADPS2
was identified in a single individual out of 2,026 healthy children
through SNP-microarray analysis (Shaikh et al, 2009; nsv 524192 in
Table 2. The two CADPS2 DMRs (differentially methylated regions) validated by the MassARRAY analysis
DMR ID Gene
cnt1 cnt2 cnt3
Cerebellum Blood Amygdala Cerebellum Amygdala Amygdala
Intron1CpG_15 CADPS2 0.000 0.243 0.230 0 0.185 0.215
P < 0.0001a P = 0.0007
P = 0.0012b
Intron1CpG_16 CADPS2 0.047 0.273 0.390 0.025 0.265 0.300
P = 0.0001a P = 0.0338
P = 0.0102b
SQNM IGF2 0.240 0.253 0.460 0.280 0.340 0.360
P = 0.7244 P = 0.0859b
aStudent’s t-test (unpaired).
bP-values calculated between all cerebella and amygdala data.
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DGV); this CNV is of unknown functional significance and parental
origin is not reported.
The relatively small intragenic deletion of CADPS2 that we identi-
fied has not been reported before and we could not detect any
CADPS2 transcript in the blood of the two affected sibs carrying the
deletion, suggesting that the maternal deleted allele is subjected to
early mRNA decay and the undeleted paternal allele is not
expressed.
Our findings point to a specific maternal expression of CADPS2
in the blood, but also in the amygdala, that plays a critical role in
social behavior (as part of the “social brain”) and dysfunction of
which has been implicated as a contributing factor in ASD (Schultz,
2005). The function of CADPS2 in amygdala has not yet been eluci-
dated, nor its expression variation during development. However,
recent published data have shown that human CADPS2 expression
is lower in the prenatal period and starts to increase in late fetal
stage until mid-childhood in amygdala; the same trend is shown in
cerebellum and neocortex (Kang et al, 2011).
A complex network involving amygdala and neurotrophin regu-
lation emerges from studies in mice where changes in Bdnf methyla-
tion pattern were found during contextual fear learning (Suri et al,
2013), and from studies showing dysfunctions in amygdala
and neurotrophin levels in neuropsychiatric disorders such as
schizophrenia and depression (Nurjono & Chong, 2012; Kuhn et al,
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Figure 4. Colony screening for parent-of-origin methylation analysis.
A Colonies carrying either the T (unmethylated, white circle) or the C (methylated, black circle) alleles at CpG_14, CpG_15, and CpG_16 and either G (green) or A (red)
alleles at SNP rs981321 (A/G in CADPS2 intron 1 PCR product; sequencing analysis performed on the colonies carrying the PCR product for intron 1 obtained from
bisulfite-treated blood DNA of a heterozygous individual for SNP rs981321.
B Histogram showing the ratio of colonies with the C methylated allele, for each CpG, for each rs981321 allele. Lower line: number of colonies carrying the C methylated
allele out of the total number of colonies with the same allele at rs981321. Significant P-values are marked with star (Fisher’s exact test).
C Parental origin of the methylated and unmethylated alleles at CpG_14, CpG1_15, and CpG_16 for three individuals for whom parental origin of alleles at rs981321
was known as shown in the figure.
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2014) . Mutation in CADPS2, leading to its dysfunction, may alter
these circuits.
We have identified maternally inherited putative damaging vari-
ants in ID/ASD cases. Sequencing of CADPS2 had been previously
performed on 90 autistic patients, but no disease-specific variants
were identified (Cisternas et al, 2003), while eight heterozygous
missense variants were identified in a cohort of 252 Japanese autistic
patients (Sadakata et al, 2007b); these variants were not investigated
further, but it is worth noting that a p. Asp1112Asn was listed, which
is adjacent and similar to one of the variants reported in the present
paper. However, determining their effects is still a matter of ques-
tion, since very few CADPS2-interacting proteins have been reported
so far, and its exact role in neurotrophin release is not completely
clear (Sadakata et al, 2007a, 2012a; Shinoda et al, 2011). Of note,
mouse tissue cDNA P20 
C57B/6  mother FVB father 
X
T T T G T T T C G T 
A 
amygdala 
T T n G T 
B 
mouse tissue cDNA E17.5 
mouse tissue cDNA P5 
cerebellum cerebral cortex kidney heart 
T T n G T T T n G T T T n G T T T n G T 
T T T G T T T n G T T T n G T T T n G T 
T T n G T T T n G T T T n G T T T n G T 
rs33756726
Figure 5. Cadps2 expression in different mouse tissues from animals heterozygous for SNP rs33756726.
A Electropherograms of rs33756726 sequence in the parental genomic DNAs, showing that the mother C57/B6 is homozygous T and the father FVB is homozygous C.
B Electropherograms showing rs33756726 allelic expression in different tissue cDNAs from the heterozygous offspring at different developmental stages (E17.5 d.p.c., P5,
P20). A monoallelic expression is visible in the cerebellum at embryonic developmental stage E17.5.
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we could observe that one of the novel changes identified in this
study, p. Asp1113Asn, disrupted CADPS2 binding to the dopamine
receptor type 2, one of its few known interactors. However, its final
effect on brain development and function is still far from being
elucidated. Indeed, shaping human behavioral traits in animal models
can be a challenge: The first study on Cadps2 showed that only null
homozygous mice had “autistic behaviors” and cerebellar defects
(Sadakata & Furuichi, 2010), although later some “autistic traits”
were also reported in heterozygous mice, even if the differences with
wild-type animals were not statistically significant (Sadakata et al,
2013). Recently, behavior abnormalities were identified in homozy-
gous mice expressing a Cadps2 isoform lacking exon 3, previously
associated with ASD and low IQ in humans (although these data are
still controversial) (Sadakata et al, 2012b, 2013). Our data showed
that CADPS2 maternal expression in the adult amygdala is not
conserved in mice; however, we identified a previously unreported
monoallelic maternal expression in embryonal mouse cerebellum,
suggesting that tissue- and temporal-specific monoallelic expression
is present for CADPS2 gene in mice and humans. Although we could
not provide evidence for a parent-of-origin-specific methylation for
CADPS2, further gene expression and methylation analyses of
CADPS2 genomic region, in diverse brain areas and at different
developmental stages, are warranted in order to clearly elucidate the
complex regulation pattern of this gene.
It is worth noting that from the comparison of the genome of
prehistoric hominids, such as Neanderthals, with the present-day
human genome CADPS2 appears to have advanced during evolution
to become a human trait-specific gene; the region containing
CADPS2 is one of the genomic intervals where positive selection in
early modern humans was detected (Green et al, 2010). The addi-
tional regulation of CADPS2 expression via monoallelic expression
in the amygdala, which plays a key role in regulating social interac-
tions, supports the importance of a fine modulation of CADPS2 for
human behavior.
Therefore, it is essential to reinterpret the available data on
CADPS2 variants (both sequence and copy number) gathered in
other studies in light of parent-of-origin effect, in order to validate
the role of CADPS2 in neurodevelopmental disorders. Furthermore,
large cohorts of trios of ID (Vissers et al, 2010) and ASD (Iossifov
et al, 2012; Neale et al, 2012; O’Roak et al, 2012; Sanders et al,
2012) patients filtered for de novo variants (Veltman & Brunner,
2012) could be reassessed in order to verify whether additional
maternally transmitted CADPS2 variants are present.
We expect that regulatory mechanisms such as the one reported
for CADPS2 may contribute to the pathogenetic effect of variants
and copy number variations in other genes inherited from otherwise
healthy parents.
Materials and Methods
Patients and controls
Patients with CADPS2 deletion
The intragenic CADPS2 deletion was identified in 2 siblings with
similar clinical features, recruited in the framework of the FP-7
supported project CHERISH, which was approved by the local ethical
review board. A 35-year-old man was followed for developmental
delay and suffered a first generalized seizure at 5 years of age, when
anti-epileptic therapy was initiated with good control. He was not
self-sufficient and was reported to suffer frequent temper tantrums.
Brain MRI and interictal EEG were normal. He did not have major
birth defects, but an abdominal CT scan detected a supernumerary
spleen. Currently, he has normal stature but is obese (height
178 cm, weight 111 kg, BMI 35). IQ evaluation (WAIS), performed
at age 30, showed a borderline cognitive impairment. His sister,
33 years old, had seizures starting at age of 18 months, partially
controlled by therapy, with an EEG showing paroxysmal parieto-
temporal activity. IQ score (WAIS), at 28 years of age, was 76; brain
MRI is normal. She is overweight (height 168 cm, weight 85 kg, BMI
30). They do not have other siblings.
ASD/ID individuals selected for CADPS2 mutation screening
ID patients were recruited in the framework of the project CHERISH.
Before inclusion in the study, all patients underwent a detailed clini-
cal ascertainment, routine molecular analysis to exclude fragile-X
syndrome and metabolic disorders. 104 ID patients were recruited
and were analyzed for CNV using the Agilent platform 44 K. 36
patients not showing any pathogenic rearrangement were included
in CADPS2 molecular mutation screening.
The patient carrying the pVal1137Met variant is a 22-year-old
man. His family history is positive for kidney malformation (in a
maternal aunt) and epilepsy (in the daughter of father’s first
cousin). The patient was born after an uneventful pregnancy but
had perinatal distress, and presented preaxial polydactyly of his left
hand. Psychomotor development was characterized by motor clum-
siness and mild language delay. The first epileptic seizure occurred
at 3 years and was characterized by left eye deviation, loss of
contact, and hypertonia of the left side of the body. During follow-
up, different seizures were observed: head nodding with upward
deviation of the eyes; focal seizures with sudden fall. Seizures were
difficult to control and their frequency was recently reduced with
lamotrigine, clobazam, and levetiracetam. Clinical examination at
16 years showed macrocrania with occipital frontal circumference
(OFC) of 60 cm, no major facial dysmorphisms, motor clumsiness,
genu valgum, flat feet, obesity (height 168 cm, weight 102 kg, BMI
36), and mild intellectual disability (WISC-R). EEG recordings
showed multifocal, diffuse, and generalized paroxysmal abnormali-
ties. Brain MRI, fundus oculi examination, and abdominal ultra-
sound scan were normal.
The 94 Italian ASD individuals include 71 probands recruited at
the Stella Maris Clinical Research Institute for Child and Adolescent
Neuropsychiatry (Calambrone, Pisa, Italy), and 23 probands
assessed at the Division of Child Neurology and Psychiatry, Depart-
ment of Pediatrics, University of Catania. ASD diagnosis was based
on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS). A clinical evaluation was
undertaken to exclude known medical disorders etiologically associ-
ated with autism (i.e., tuberous sclerosis, neurofibromatosis). Stan-
dard karyotyping, fragile-X testing, and EEG were obtained on all
patients, and brain MRI was performed whenever possible. The
male/female ratio of the affected individuals is 5.3:1.
Ninety-three additional unrelated probands with ASD were
selected from 293 IMGSAC multiplex families. IMGSAC assessment
methods and inclusion criteria used have been described previously
(IMGSAC, 2001).
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A blood sample was drawn from the propositus/a and available
first-degree relatives.
The patient carrying the p. Asp1113Asn change was the first child
of healthy non-consanguineous parents, born at term by spontane-
ous delivery after a pregnancy with no exposure or history of chronic
illnesses, alcohol, tobacco, or street drugs. Family history was non-
contributory. Birth weight was 3,200 g (50th centile), length 51.3 cm
(50th centile), and OFC 33.8 cm (30th centile). Apgar was 10. She
was breastfed for 2 months, thereafter fed with formula without any
difficulties. Weaning to solid food was regular. She walked alone at
13 months. First words were reported around her first birthday. At
4 years, she was able to pronounce complete sentences with unintel-
ligible speech verbal productions, pronominal inversions, and echo-
lalia. She was withdrawn from early on, showing no interest toward
her peers, being passive with inconstant eye-to-eye contact, with low
level of frustration tolerance, and restricted interests. Play was very
poor and repetitive. Gestual stereotypies were also observed. At
kindergarten, she showed separation anxiety from her mother.
Attention deficit and learning difficulties were reported in primary
school. Sleep–wake rhythm was irregular, with frequent nocturnal
awakenings. At age of 4 years, she started psychomotor and psycho-
logic therapy and attended school with the help of a supporting
teacher. ECG, EEG, brain MRI, complete metabolic work-up, and
screening for celiac disease were normal. We first saw her at the age
of 6 years. On physical examination, there were no dysmorphic
features. Height was 123 cm (97th centile), weight 24 kg (90th
centile), and OFC 51.5 cm (50th centile). Neurologic examination
showed mild joint laxity and diffuse hypotonia. Language was char-
acterized by the production of simple phrases with impaired prosody
and, on occasion, echolalia. Comprehension was adequate whenever
she paid attention to the verbal message. She had a mild cognitive
impairment (WPPSI) without significant differences between verbal
and performance competences. The evaluation for PDDs gave scores
in keeping with a clinical diagnosis of PDD-NOS. Over time, she
showed a slow, but constant, overall improvement.
Human brain tissues
Human brain samples from frontal cerebral cortex, amygdala,
entorhinal cortex and cerebellum were obtained from deep-frozen
(80°C) slices of 3 adults showing either no significant histopatho-
logical changes (a 41-year-old woman) or neurodegenerative histo-
pathological lesions of variable severity (a 78-year-old woman with
mild AD pathology, and a 78-year-old man with dementia with
Lewy bodies of neocortical subtype (Montine et al, 2012)).
All data from either patients or their caretakers and controls,
including the informed consent, were handled in accordance with
the local ethical committee’s approved protocols and in compliance
with the Helsinki declaration. Written informed consent for research
use, given by the patients during life or by their next of kin after
death, was also available for brain tissues used for RNA analyses.
Array-CGH
Genomic DNA was extracted from peripheral blood and its quality
was monitored using a NanoDrop spectrophotometer (Thermo
Scientific, DE, USA). The entire array-CGH procedure performed
according to the Agilent protocol for the 44K platform (Agilent
Technologies, CA, USA). The new CADPS2 deletion has been
deposited in the ArrayExpress database (accession number:
E-MTAB-2124).
Microsatellite analysis
Two microsatellite markers mapping to CADPS2 intron 1 (CAD-
PS2_21xAC, genomic position: chr7:122,414,324-122,414,365) and
intron 2 (CADPS2_26xAT, genomic position: chr7:122,348,575-
122,348,626) were genotyped from blood-derived DNA of father,
proband, and affected sister according to the following PCR condi-
tions: 30 ng genomic DNA, 2.5 mM MgCl2, 0.2 mM dNTPs, 0.5 lM
primers (FAM-labeled), in a final volume of 10 ll using 0.25 unit of
Gold Taq Polymerase (Life Technologies). A touch-down program
of forty cycles was carried out as follows: 95°C 50, 95°C 300 0, 62–57°
C, 72°C 300 0 for 10 cycles, followed by 30 cycles at 95°C 300 0, 57°C
300 0, 72°C 300 0 with a final extension of 70 at 72°C. Samples were
diluted 1/10 and 1 ll of dilution was run onto the automated 3730
ABI sequencing machine with LIZ(500) size marker (Life Technolo-
gies, Foster City, CA, USA). Genotype call was performed with
GeneMapper v3.7.
Real-time quantitative PCR
Quantitative PCR of CADPS2 exons 3, 4, 6, 7, 26, 28, and 29 was
carried out in blood-derived DNA from father, proband, affected
sister, and one control sample, using Sybr-Green (Life Technolo-
gies). A region on FOXP2 gene was amplified as internal control.
PCR primers and conditions are available on request. Melting curve
analysis of each PCR product was carried out to ensure specific
amplification, and PCR efficiencies were calculated using a dilution
series of DNA template. All samples were run in triplicate on the
ABI7500 Fast PCR machine (Life Technologies). Relative copy
number was calculated using the comparative Ct method, taking
PCR efficiency into account.
CADPS2 breakpoint cloning
PCR primers for CADPS2 deletion breakpoint cloning were designed
with Primer3 v4.0 as follows: forward 50-GGCAGAGAGGATGACG-
TAG-30; reverse 50-CTGGATGGAGAAGAGCTGGA-30. A long-range
PCR was performed using the Expand-Long Range PCR kit according
to the manufacturer’s instruction (Roche Diagnostics) using 200 ng
of genomic DNA from peripheral blood with the following PCR
cycles (40): 92°C 20, 92°C 100 0 60°C 150 0 68°C 140, 68°C 70.
PCR products were purified onto a Millipore PCR clean-up plate,
cloned with the Original TA cloning kit (Life Technologies) in the
pcDNA2.1 vector, and transformed into DH5a E. coli strains for
white/blue screening. White colonies were grown and the plasmid
DNA was purified and sequenced with universal M13 forward and
reverse primers using the BigDye v1.1 kit (Life Technologies).
Sequences were run onto the ABI 3730 automated sequencing
machine, and electropherograms were analyzed with Chromas
version 2.0.
Mutation screening
PCR primers for human CADPS2 (NM_017954.10) were designed
with Primer3 v4.0. Genomic DNA extracted from peripheral blood
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was amplified according to the following PCR conditions: 30 ng of
DNA, 2.5 mM MgCl2, 0.5 mM dNTPs, 0.5 lM primers, 5% DMSO
in a final volume of 20 ll using the KAPA Fast Taq Polymerase
Master mix (KAPA Biosystems, MA, USA). Forty cycles were
carried out as follows: 95°C 10, 95°C 150 0, 58°C 150 0, 72°C 200 0, with
a final extension of 300 0 at 72°C. PCR products were purified onto
Millipore PCR clean-up plates and directly sequenced on both
strands using the BigDye v1.1 kit (Life Technologies). Electrophero-
grams were visualized with Chromas version 2.0 and Sequencer
version 4.7.
SNPs rs2074589 (chr7 g.122,078,414T > G) in exon 17 and
rs20784589 (chr7 g.122,033,379A > G) in exon 22 were genotyped
using the same PCR primers and conditions utilized for mutation
screening.
CADPS2 missense change analysis
Human CADPS2 cDNA clone (NM_017954.10) was a kind gift of
Dr. I. Eckhardt (Max-Planck-Institut fu¨r Experimentelle Medizin,
Go¨ttingen, Germany). The coding sequence was PCR-amplified
and inserted in frame to the C-ter V5 tag in pcDNA3.1 vector
using Pfx Taq Polymerase (Life Technologies) and site-directed
mutagenesis was carried out using the QuickChange XL muta-
genesis kit (Agilent Technologies) according to the manufacturer’s
instructions. All PCR conditions and primers are available on
request. The insertion of the changes was verified by sequencing.
3 × 105 SHSY5Y human neuroblastoma cells (ATCC, UK) were
plated for transfection of the different plasmids using liposomes
according to the manufacturer’s instructions (Lipofectamine, Life
Technologies). Forty-eight hours after transfection, cells were
lysed in 50 mM HEPES, 1 mM EDTA, 10% glycerol, 1% Triton
X-100, 150 mM NaCl in the presence of protease inhibitors
(Roche Diagnostics) and phosphatase inhibitors (Inhibition Cock-
tail 2 and 3, Sigma). Pre-clearing was performed with rabbit IgG
(Millipore) for 1 h at 4°C. Immunoprecipitation assays were
performed at 4°C using 0.8 lg rabbit anti-D2DR antibody/reaction
(Santa Cruz, CA, USA) or 1 lg mouse anti-V5 antibody/reaction
(Life Technologies) on Protein G-Sepharose (Sigma). Proteins
were separated by SDS gel electrophoresis, transferred onto nitro-
cellulose membrane (GE Healthcare, UK), and subjected to
western blotting with the Western Breeze kit (Life Technologies).
Primary antibodies used were the following: mouse anti-V5 (Life
Technologies) diluted at 1:5,000; mouse anti-tubulin gamma
(Sigma) diluted at 1:10,000; rabbit anti-D2DR (Santa Cruz)
diluted at 1:150. Bands were visualized by the ECL method (GE
Healthcare).
CADPS2 expression analysis
Total RNA from 1.5 ml fresh blood was extracted with the
QIAGEN Blood Total RNA kit (QIAGEN, MD, USA). Total RNA
from 5 × 106 lymphoblastoid cells, cultured as described (Bonora
et al, 2002) or from human frozen brain tissues (30–40 mg) was
extracted using with the QIAGEN Total RNA kit (QIAGEN). Tissues
from F1 mice, obtained by crossing FVB (father) × C57B/6
(mother) lines, were obtained at different developmental stages
from animals sacrificed by cervical dislocation. Kidney, heart, cere-
bellum, cerebral cortex, and amygdala were collected for RNA
extraction and RT–PCR as described above. All animal procedures
were carried out at San Raffaele Scientific Institute, Milan, Italy,
according to, and approved by, the San Raffaele Institutional
Animal Care and Use Committee.
One microgram of DNase I-treated RNA was used for reverse
transcription with random hexamers using the Multiscribe RT
system (Life Technologies) at 48°C for 400 in a final volume of 50 ll.
Six microliters of cDNA was used for testing CADPS2/Cadps2
expression in human and mouse tissues, respectively. All primer
pairs are available on request. PCR conditions were the following:
2.5 mM MgCl2, 0.5 mM each dNTP, 0.5 lM primers, 5% DMSO in a
final volume of 50 ll using the KAPA Fast Master mix (KAPA
Biosystems). Forty-six cycles were carried out at 95°C 10, 95°C 150 0,
58°C 150 0, 72°C 200 0, 10 at 72°C. PCR products were purified and
sequenced as described before.
MALDI-TOF MS methylation analysis
DNA methylation of CADPS2 gene was determined by gene-specific
amplification using in vitro transcription coupled with mass spec-
trometry (MS) (MassARRAY platform, Sequenom, CA, USA; Ehrich
et al, 2005; Di Vinci et al, 2012). One microgram of genomic DNA
was submitted to bisulfite conversion, using the EZ DNA Methyla-
tion Kit (Zymo Research, CA, USA), according to the manufac-
turer’s protocol, except for the conversion step consisting of 21
cycles at 95°C for 30 s and 50°C for 15 min. Universal unmethylated
and methylated DNAs (Millipore, MA, USA) were used as internal
controls. In addition, a 477-bp amplicon for the IGF2 region
was included in the assay for quality assessment of bisulfite-
treated DNA. A region length spanning 1.9 kb of promoter and
1.8 kb of intron 1 of CADPS2 gene (corresponding to genomic
coordinates chr7: 122,524,253–122,528,311, hg19) was submitted
to EpiDesigner BETA software (Sequenom) for predicting the CpG
islands. Four amplicons including 92 CpGs were selected; 63 of
these CpGs were analyzable through this methodology (Supple-
mentary Table S3).
The protocol employed a T7-promoter-tagged PCR amplification
of bisulfite-converted DNA, followed by the generation of single-
stranded RNA molecule and subsequent base-specific cleavage by
RNase A. 25 ll H2O MilliQ and 4 lg resin were added to the
cleaved fragments. 20 nl of the analytes was nanodispensed onto
384-element silicon chips preloaded with matrix. Mass spectra were
collected by using a matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) MS, and spectra’s methylation ratios
were generated by EpiTYPER software V.1.2.22. Samples were run
in duplicate/triplicate when possible. The different cleavage prod-
ucts created from methylated or non-methylated target regions
generate characteristic signal patterns that provide straightforward
analysis by MALDI-TOF mass spectrometry. In analyzing the mass
spectrum, the relative amount of methylation is calculated by
comparing the difference in signal intensity between mass signals
derived from methylated and non-methylated template DNA. The
numerical value for each detected CpG unit/site is the detected
methylation ratio found at that CpG unit/site after being treated
with the bisulfite solution. Result data with blank cells are the
result of the maximum level of uncertainty not being met. The
maximum uncertainty level is entered as the uncertainty threshold.
The recommended value for uncertainty threshold is 0.1, according
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to the manufacturer’s instructions, and any data with an estimated
error larger than this value were excluded (a small value entered
for this threshold causes the data displayed to exclude the more
imprecise data and include more precise data for the selected
amplicon). Sequenom peaks with reference intensity above 2,
overlapping and duplicate units were excluded from the analysis
(Izzi et al, 2012).
Statistical analysis
Differences in frequencies between cases and controls were evalu-
ated using the Fisher’s exact test; quantitative differences in methyl-
ation ratio were evaluated using the Student’s t-test (unpaired
t-test); differences in the number of colonies carrying the methylated
vs unmethylated alleles were calculated using the Fisher’s exact
test.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
Acknowledgements
We thank all the patients, families, and healthy volunteers that participated in
the study. We thank Prof. A. Contestabile for the support in mouse brain
expression analysis and Ms. M. Giambartolomei and Dr. M. Vidone for techni-
cal help. This work was supported by FP7-EU Grant No 223692 “CHERISH” to
G. R.
Author contribution
EB, CG, EM, EB and MS designed the experimental plan, analyzed the data,
and wrote the manuscript; FM and SL performed the mutation analysis and
allelic expression; PM performed CNV analysis; CD, EM and VM performed
quantitative methylation analysis; FB and MV performed the western
blotting experiments; PP provided the human brain tissues; LR and MT
provided the mouse tissues; AP, AB, LM, GT, the IMGSAC Consortium, and
Giovanni Romeo provided ASD and ID samples and performed the clinical
evaluation.
Conflict of interest
The authors declare that they have no conflict of interest.
For more information
http://www.cirp.org/library/ethics/helsinki
http://www.cherishproject.eu
http://dgv.tcag.ca/dgv/app/home
https://www.iscaconsortium.org/index.php
http://gvarianti.homelinux.net/gvariantib37/index.php
http://www.ebi.ac.uk/arrayexpress
http://rulai.cshl.edu
http://www.umd.be/HSF/
http://www.ncbi.nlm.nih.gov/SNP
http://www.1000genomes.org
http://evs.gs.washington.edu/EVS/
http://hbatlas.org/
References
Adzhubei I, Jordan DM, Sunyaev SR (2013) Predicting Functional Effect of
Human Missense Mutations Using PolyPhen-2. Current protocols in
human genetics/editorial board, Jonathan L Haines [et al.] Chapter 7:
Unit7 20.
Autism and Developmental Disabilities Monitoring Network Surveillance Year
2006 Principal Investigators; Centers for Disease Control and Prevention C
(2009) Prevalence of autism spectrum disorders - Autism and
Developmental Disabilities Monitoring Network, United States, 2006.
MMWR Surveill Summ 58: 1 – 20
Binda AV, Kabbani N, Levenson R. (2005) Regulation of dense core vesicle
release from PC12 cells by interaction between the D2 dopamine receptor
and calcium-dependent activator protein for secretion (CAPS). Biochem
Pharmacol 69: 451 – 461
van Bokhoven H (2011) Genetic and epigenetic networks in intellectual
disabilities. Annu Rev Genet 45: 81 – 104
The paper explained
Problem
Intellectual disability (ID) is a neurodevelopmental disorder character-
ized by a below-average score on tests of mental ability and limita-
tions in daily life functions. Autism spectrum disorders (ASDs) are
characterized by impaired social interactions and communication,
stereotyped behaviors, and onset before 3 years of age. Both disorders
are severe neuropsychiatric conditions, with overlapping clinical
boundaries in many patients. Structural variants and single base pair
mutations in genes involved in synaptic function have been identified
in neurodevelopmental disorders; nevertheless, their pathogenic role is
often unclear and causative mutations are still not found in a large
proportion of patients.
Results
We identified a novel intragenic deletion in two siblings with border-
line cognitive decline and epilepsy in CADPS2 gene, encoding for a
synaptic protein involved in neurotrophin release and interaction with
dopamine receptor type 2 (D2DR).
Mutation screening in additional patients (187 with ASD and 36 with
ID) identified several variants of maternal origin, including a missense
change disrupting CADPS2/D2DR interaction. We showed that CADPS2
was monoallelically expressed in blood and amygdala, and the
expressed allele in the two tissues was the one of maternal origin.
Few differentially methylated sites were identified in CADPS2 first
intron, in blood and amygdala, but they did not show a parent-of-
origin methylation pattern typical of an imprinted gene. Nevertheless,
we suggest that further gene expression and methylation analyses of
CADPS2 genomic region, in diverse brain areas and at different devel-
opmental stages, are warranted in order to clearly elucidate the
complex regulation pattern of this gene.
Impact
We provide the first evidence that CADPS2 shows a tissue-specific
monoallelic expression, with only the maternally inherited allele
expressed in human blood and in specific brain regions (in the amyg-
dala to the least), and we indicate that CADPS2 maternally inherited
mutations can contribute to ID/ASD. We expect that regulatory mech-
anisms such as the one we discovered for CADPS2 may contribute to
the pathogenetic effect of variants and copy number variations inher-
ited from otherwise healthy parents in other genes. In particular, we
suggest that the available data on CADPS2 variants (both sequence
and copy number) gathered in other studies should be interpreted in
light of parent-of-origin effect, in order to corroborate the role of
CADPS2 in neurodevelopmental disorders.
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 6 | 2014
Elena Bonora et al Maternally expressed CADPS2 gene in ASD/ID EMBO Molecular Medicine
807
Published online: April 14, 2014 
Bonora E, Bacchelli E, Levy ER, Blasi F, Marlow A, Monaco AP, Maestrini E,
International Molecular Genetic Study of Autism C (2002) Mutation
screening and imprinting analysis of four candidate genes for autism in
the 7q32 region. Mol Psychiatry 7: 289 – 301
Cisternas FA, Vincent JB, Scherer SW, Ray PN (2003) Cloning and
characterization of human CADPS and CADPS2, new members of the
Ca2+-dependent activator for secretion protein family. Genomics 81:
279 – 291
Coe BP, Girirajan S, Eichler EE (2012) The genetic variability and commonality
of neurodevelopmental disease. Am J Med Genet C, Semin Med Genet 160C:
118 – 129
Di Vinci A, Casciano I, Marasco E, Banelli B, Ravetti GL, Borzi L, Brigati C,
Forlani A, Dorcaratto A, Allemanni G et al (2012) Quantitative
methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association
with tumor WHO grade and clinical outcome. J Cancer Res Clin Oncol 138:
35 – 47
Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G,
Cantor CR, Field JK, van den Boom D (2005) Quantitative high-
throughput analysis of DNA methylation patterns by base-specific
cleavage and mass spectrometry. Proc Natl Acad Sci USA 102:
15785 – 15790
Fombonne E (2005) Epidemiology of autistic disorder and other pervasive
developmental disorders. J Clin Psychiatry 66(Suppl 10): 3 – 8
Gilman SR, Iossifov I, Levy D, Ronemus M, Wigler M, Vitkup D (2011) Rare de
novo variants associated with autism implicate a large functional network
of genes involved in formation and function of synapses. Neuron 70:
898 – 907
Green RE, Krause J, Briggs AW, Maricic T, Stenzel U, Kircher M, Patterson N, Li
H, Zhai W, Fritz MH et al (2010) A draft sequence of the Neandertal
genome. Science 328: 710 – 722
International Molecular Genetic Study of Autism Consortium (IMGSAC) (2001)
A genomewide screen for autism: strong evidence for linkage to
chromosomes 2q, 7q, and 16p. Am J Hum Genet 69: 570 – 581
Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, Yamrom B,
Lee YH, Narzisi G, Leotta A et al (2012) De novo gene disruptions in
children on the autistic spectrum. Neuron 74: 285 – 299
Izzi B, Francois I, Labarque V, Thys C, Wittevrongel C, Devriendt K, Legius E,
Van den Bruel A, D’Hooghe M, Lambrechts D et al (2012) Methylation
defect in imprinted genes detected in patients with an Albright’s
hereditary osteodystrophy like phenotype and platelet Gs hypofunction.
PLoS ONE 7: e38579
Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X, Li M, Sousa AM, Pletikos M,
Meyer KA, Sedmak G et al (2011) Spatio-temporal transcriptome of the
human brain. Nature 478: 483 – 489
Kosaki K, Kosaki R, Craigen WJ, Matsuo N (2000) Isoform-specific imprinting
of the human PEG1/MEST gene. Am J Hum Genet 66: 309 – 312
Kuhn M, Popovic A, Pezawas L (2014) Neuroplasticity and memory formation
in major depressive disorder: an imaging genetics perspective on
serotonin and BDNF. Restor Neurol Neurosci 32: 25 –49
Lamb JA, Barnby G, Bonora E, Sykes N, Bacchelli E, Blasi F, Maestrini E,
Broxholme J, Tzenova J, Weeks D et al (2005) Analysis of IMGSAC autism
susceptibility loci: evidence for sex limited and parent of origin specific
effects. J Med Genet 42: 132 – 137
Lee YJ, Park CW, Hahn Y, Park J, Lee J, Yun JH, Hyun B, Chung JH (2000) Mit1/
Lb9 and Copg2, new members of mouse imprinted genes closely linked to
Peg1/Mest(1). FEBS Lett 472: 230 – 234
Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW,
Duyckaerts C, Frosch MP, Masliah E, Mirra SS et al (2012) National
Institute on Aging-Alzheimer’s Association guidelines for the
neuropathologic assessment of Alzheimer’s disease: a practical approach.
Acta Neuropathol 123: 1 – 11
Neale BM, Kou Y, Liu L, Ma’ayan A, Samocha KE, Sabo A, Lin CF, Stevens C,
Wang LS, Makarov V et al (2012) Patterns and rates of exonic de novo
mutations in autism spectrum disorders. Nature 485: 242 – 245
Nurjono ML, Chong SA (2012) A Review of Brain-derived Neurotrophic Factor
as a Candidate Biomarker in Schizophrenia. Clin Psychopharmacol Neurosci
10: 61 – 70
Okamoto N, Hatsukawa Y, Shimojima K, Yamamoto T (2011)
Submicroscopic deletion in 7q31 encompassing CADPS2 and TSPAN12 in a
child with autism spectrum disorder and PHPV. Am J Med Genet A 155A:
1568 – 1573
O’Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, Levy R, Ko A, Lee
C, Smith JD et al (2012) Sporadic autism exomes reveal a highly
interconnected protein network of de novo mutations. Nature 485:
246 – 250
Riesewijk AM, Hu L, Schulz U, Tariverdian G, Hoglund P, Kere J, Ropers HH,
Kalscheuer VM (1997) Monoallelic expression of human PEG1/MEST is
paralleled by parent-specific methylation in fetuses. Genomics 42:
236 – 244
Sabens EAD, Mieyal JJ (2010) Levodopa deactivates enzymes that regulate
thiol-disulfide homeostasis and promotes neuronal cell death:
implications for therapy of Parkinson’s disease. Biochemistry 49:
2715 – 2724
Sadakata T, Furuichi T (2009) Developmentally regulated Ca2+-dependent
activator protein for secretion 2 (CAPS2) is involved in BDNF secretion and
is associated with autism susceptibility. Cerebellum 8: 312 – 322
Sadakata T, Furuichi T (2010) Ca(2+)-dependent activator protein for
secretion 2 and autistic-like phenotypes. Neurosci Res 67: 197 – 202
Sadakata T, Itakura M, Kozaki S, Sekine Y, Takahashi M, Furuichi T (2006)
Differential distributions of the Ca2+-dependent activator protein for
secretion family proteins (CAPS2 and CAPS1) in the mouse brain. J Comp
Neurol 495: 735 – 753
Sadakata T, Kakegawa W, Mizoguchi A, Washida M, Katoh-Semba R, Shutoh
F, Okamoto T, Nakashima H, Kimura K, Tanaka M et al (2007a) Impaired
cerebellar development and function in mice lacking CAPS2, a protein
involved in neurotrophin release. J Neurosci 27: 2472 – 2482
Sadakata T, Mizoguchi A, Sato Y, Katoh-Semba R, Fukuda M, Mikoshiba K,
Furuichi T (2004) The secretory granule-associated protein CAPS2
regulates neurotrophin release and cell survival. J Neurosci 24: 43 – 52
Sadakata T, Sekine Y, Oka M, Itakura M, Takahashi M, Furuichi T (2012a)
Calcium-dependent activator protein for secretion 2 interacts with the
class II ARF small GTPases and regulates dense-core vesicle trafficking.
FEBS J 279: 384 – 394
Sadakata T, Shinoda Y, Oka M, Sekine Y, Furuichi T (2013) Autistic-like
behavioral phenotypes in a mouse model with copy number variation of
the CAPS2/CADPS2 gene. FEBS Lett 587: 54 – 59
Sadakata T, Shinoda Y, Oka M, Sekine Y, Sato Y, Saruta C, Miwa H, Tanaka M,
Itohara S, Furuichi T (2012b) Reduced axonal localization of a Caps2 splice
variant impairs axonal release of BDNF and causes autistic-like behavior
in mice. Proc Natl Acad Sci USA 109: 21104 – 21109
Sadakata T, Washida M, Iwayama Y, Shoji S, Sato Y, Ohkura T, Katoh-Semba
R, Nakajima M, Sekine Y, Tanaka M et al (2007b) Autistic-like phenotypes
in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic
patients. J Clin Invest 117: 931 – 943
Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ,
Ercan-Sencicek AG, DiLullo NM, Parikshak NN, Stein JL et al (2012) De
EMBO Molecular Medicine Vol 6 | No 6 | 2014 ª 2014 The Authors
EMBO Molecular Medicine Maternally expressed CADPS2 gene in ASD/ID Elena Bonora et al
808
Published online: April 14, 2014 
novo mutations revealed by whole-exome sequencing are strongly
associated with autism. Nature 485: 237 – 241
Schneider E, Mayer S, El Hajj N, Jensen LR, Kuss AW, Zischler H, Kondova I,
Bontrop RE, Navarro B, Fuchs E et al (2012) Methylation and expression
analyses of the 7q autism susceptibility locus genes MEST, COPG2, and
TSGA14 in human and anthropoid primate cortices. Cytogenet Genome Res
136: 278 – 287
Schultz RT (2005) Developmental deficits in social perception in autism: the
role of the amygdala and fusiform face area. Int J Dev Neurosci 23:
125 – 141
Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O’Hara R,
Casalunovo T, Conlin LK, D’Arcy M et al (2009) High-resolution mapping
and analysis of copy number variations in the human genome: a data
resource for clinical and research applications. Genome Res 19: 1682 – 1690
Shinoda Y, Sadakata T, Nakao K, Katoh-Semba R, Kinameri E, Furuya A,
Yanagawa Y, Hirase H, Furuichi T (2011) Calcium-dependent activator
protein for secretion 2 (CAPS2) promotes BDNF secretion and is critical for
the development of GABAergic interneuron network. Proc Natl Acad Sci
USA 108: 373 – 378
Suri D, Veenit V, Sarkar A, Thiagarajan D, Kumar A, Nestler EJ, Galande S,
Vaidya VA (2013) Early stress evokes age-dependent biphasic changes in
hippocampal neurogenesis, BDNF expression, and cognition. Biol
Psychiatry 73: 658 – 666
Veltman JA, Brunner HG (2012) De novo mutations in human genetic disease.
Nat Rev Genet 13: 565 – 575
Vissers LE, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, van Lier
B, Arts P, Wieskamp N, del Rosario M et al (2010) A de novo paradigm for
mental retardation. Nat Genet 42: 1109 – 1112
Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor
RM, Blencowe BJ, Geschwind DH (2011) Transcriptomic analysis of
autistic brain reveals convergent molecular pathology. Nature 474:
380 – 384
License: This is an open access article under the
terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in
any medium, provided the original work is properly
cited.
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 6 | 2014
Elena Bonora et al Maternally expressed CADPS2 gene in ASD/ID EMBO Molecular Medicine
809
Published online: April 14, 2014 
